Omeros | OMER - Selling And Administration Expenses

Stock Price
13.44
Daily Change
0.90 7.18%
Monthly
22.74%
Yearly
100.60%
Q2 Forecast
11.18

Omeros reported $11.32M in Selling and Administration Expenses for its fiscal quarter ending in September of 2024.





Selling And Administration Expenses Change Date
Adma Biologics USD 20.19M 2.86M Dec/2025
Alnylam Pharmaceuticals USD 285.06M 22.47M Dec/2025
BioMarin Pharmaceutical USD 322.21M 98.79M Dec/2025
Cytokinetics USD 91.72M 67.02M Dec/2025
Gilead Sciences USD 1.78B 425M Dec/2025
Heron Therapeutics USD 23.74M 605K Dec/2025
Immunic USD -0.24 0.03 Sep/2024
Insmed USD 212.48M 26.11M Dec/2025
Knight Therapeutics CAD 35.45M 4.43M Dec/2025
MacroGenics USD 7.94M 1.96M Dec/2025
Omeros USD 11.32M 2.48M Sep/2024
Pacira USD 91.87M 70K Dec/2025
Pfizer USD 4.08B 894M Dec/2025
Rockwell Medical USD 4.04M 330K Jun/2024
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Sarepta Therapeutics USD 105.38M 28.27M Dec/2025
United Therapeutics USD 190.6M 38.6M Dec/2025
Vertex Pharmaceuticals USD 487M 41.9M Dec/2025
Xoma USD 11M 2.54M Jun/2024